Association Genethon

Association Genethon is a research organisation in Evry, France that has taken part in 20 EU-funded projects since 2008, receiving €15.7M in EU funding and leading 7 as coordinator.

EU funding received€15.7M
EU projects20
As coordinator7
Running now3
First EU project2008
Latest project2025
CountryFrance
EU registration (PIC)998217883
On this page · 5 sections→

Where the EU money came from

Funding by EU programme. Amounts are Association Genethon's own share of each project, not the project's full budget.

  • Horizon 2020€7.7M · 10 projects
  • FP7 (2007 to 2013)€6.9M · 7 projects
  • Horizon Europe€1.0M · 3 projects

Projects

20 EU-funded projects, newest first. Association Genethon led 7 of them as coordinator. Each links to the official record.

  • TEHCAssociated partner

    Towards the Engineering of High-Capacity Viral Vectors for Neuromuscular Diseases

    Horizon Europe · 2025–2027 · Project on CORDIS ↗

  • ERDERAPartner

    EUROPEAN RARE DISEASES RESEARCH ALLIANCE

    Horizon Europe · 2024–2031 · Project on CORDIS ↗

    €449ktheir share
  • AAVolutionPartner

    Next-generation AAV vectors for liver-directed gene therapy

    Horizon Europe · 2022–2027 · Project on CORDIS ↗

    €591ktheir share
  • ARDATPartner

    Accelerating Research & Development for Advanced Therapies

    Horizon 2020 · 2020–2026 · Project on CORDIS ↗

    €321ktheir share
  • MITOPOMPECoordinator

    Targeting mitochondrial defects and oxidative stress in Pompe Disease: from pathogenesis to therapy

    Horizon 2020 · 2019–2020 · Project on CORDIS ↗

    €173ktheir share
  • UshTherPartner

    Clinical trial of gene therapy with dual AAV vectors for retinitis pigmentosa in patients with Usher syndrome type IB

    Horizon 2020 · 2018–2023 · Project on CORDIS ↗

    €91ktheir share
  • CureCNCoordinator

    Adeno-Associated Virus Vector-Mediated Liver Gene Therapy for Crigler-Najjar Syndrome

    Horizon 2020 · 2018–2023 · Project on CORDIS ↗

    €4.0Mtheir share
  • DMD2CURECoordinator

    Correction of duplications in the DMD gene by a CRISPR/Cas9 approach

    Horizon 2020 · 2017–2019 · Project on CORDIS ↗

    €185ktheir share
  • Muscle stress reliefPartner

    Muscle Stress Relief: An integrated research program linking together basic research on secondary myopathies in stress states to innovative translation in applied myology.

    Horizon 2020 · 2016–2020 · Project on CORDIS ↗

    €131ktheir share
  • GLYCODIS3Coordinator

    Genetic correction of glycogen debranching enzyme deficiency in Glycogen Storage disease III: a proof of concept study

    Horizon 2020 · 2016–2017 · Project on CORDIS ↗

    €173ktheir share
  • SCIDNETPartner

    DevelopIng Genetic medicines for Severe Combined Immunodeficiency (SCID)

    Horizon 2020 · 2016–2019 · Project on CORDIS ↗

    €800ktheir share
  • MYOCUREPartner

    Development of an innovative gene therapy platform to cure rare hereditary muscle disorders

    Horizon 2020 · 2016–2019 · Project on CORDIS ↗

    €1.4Mtheir share
  • MIROCALSPartner

    Efficacy and safety of low-dose IL-2 (ld-IL-2) as a Treg enhancer for anti-neuroinflammatory therapy in newly diagnosed Amyotrophic Lateral Sclerosis (ALS) patients

    Horizon 2020 · 2015–2021 · Project on CORDIS ↗

    €374ktheir share
  • MOMAAVCoordinator

    Molecular signatures and Modulation of immunity to Adeno-Associated Virus vectors

    FP7 (2007 to 2013) · 2014–2019 · Project on CORDIS ↗

    €810ktheir share
  • EUROFANCOLENPartner

    Phase I/II Gene Therapy Trial of Fanconi anemia patients with a new Orphan Drug consisting of a lentiviral vector carrying the FANCA gene: A Coordinated International Action

    FP7 (2007 to 2013) · 2013–2018 · Project on CORDIS ↗

    €631ktheir share
  • NET4CGDCoordinator

    Gene Therapy for X-linked Chronic Granulomatous Disease (CGD)

    FP7 (2007 to 2013) · 2012–2018 · Project on CORDIS ↗

    €2.3Mtheir share
  • GT-SKINCoordinator

    Gene Therapy for Inherited Skin Adhesion Disorders

    FP7 (2007 to 2013) · 2011–2017 · Project on CORDIS ↗

    €2.2Mtheir share
  • GENEGRAFTPartner

    Phase I/II ex vivo gene therapy clinical trial for recessive dystrophic epidermolysis bullosa using skin equivalent grafts genetically corrected with a COL7A1-encoding SIN retroviral vector

    FP7 (2007 to 2013) · 2011–2017 · Project on CORDIS ↗

    €331ktheir share
  • PERSISTPartner

    Persisting Transgenesis

    FP7 (2007 to 2013) · 2009–2013 · Project on CORDIS ↗

    €497ktheir share
  • NMD-CHIPPartner

    Development of targeted DNA-Chips for High Throughput Diagnosis of NeuroMuscular Disorders

    FP7 (2007 to 2013) · 2008–2011 · Project on CORDIS ↗

    €160ktheir share

Works most with

Organisations that shared the most EU projects with this one. A good starting list for consortium partners.

Fields it works in

Research fields recorded on its Horizon projects.

  • DNA
  • amyotrophic lateral sclerosis
  • development studies
  • diabetes
  • drug discovery
  • drug safety
  • duchenne muscular dystrophy
  • ecosystems
  • enzymes
  • gene therapy
  • genomes
  • graft versus host disease
  • hematology
  • immunology

Is this your organisation?

Claim it with an EUACC listing (€39 once, reviewed by our editors): add what you build, your team and what you are looking for. We pre-fill it from your EU records. Listed companies reach investors through our newsletter and get matched to new EU calls first.

Claim this profile →

Source: CORDIS (Horizon Europe, Horizon 2020, FP7) and the EU Funding & Tenders Portal (other EU programmes), matched by the EU registration number (PIC). Past participation does not mean the organisation is open to new partnerships. Official website ↗

Europe’s tech funding.
One place.

The weekly briefing

Funding calls, VC news and key deadlines — a weekly briefing for European founders.

Free · unsubscribe anytime